Avonex(interferon beta-1a)
Avonex, Rebif (interferon beta-1a) is a protein pharmaceutical. Interferon beta-1a was first approved as Avonex on 1996-05-17. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Avonex, Rebif (discontinued: Avonex)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon beta-1a
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Avonex | interferon beta-1a | Biogen | N-103628 RX | 2003-05-28 | 2 products |
| Rebif | interferon beta-1a | EMD Serono | N-103780 RX | 2002-03-07 | 6 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avonex | Biologic Licensing Application | 2016-03-31 |
| avonex avonex avonex pen | Biologic Licensing Application | 2020-12-16 |
| avonex avonex pen | Biologic Licensing Application | 2025-11-19 |
| rebif | Biologic Licensing Application | 2010-01-14 |
| rebif rebif rebidose | Biologic Licensing Application | 2025-09-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple sclerosis | EFO_0003885 | D009103 | G35 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
interferon beta-1a, Avonex, Biogen Inc. | |||
| 2103-05-17 | Orphan excl. | ||
Patent Expiration
No data
Clinical
Clinical Trials
247 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 4 | 3 | 11 | 16 | 21 | 54 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 2 | 10 | 12 | 6 | 30 |
| Sclerosis | D012598 | — | — | — | — | 4 | 10 | 6 | 20 |
| Injection site reaction | D000075662 | — | — | — | — | — | 1 | 1 | 2 |
| Erythema | D004890 | — | L53.9 | — | — | — | 1 | — | 1 |
| Transverse myelitis | D009188 | — | G37.3 | — | — | — | 1 | — | 1 |
| Cerebellar diseases | D002526 | — | — | — | — | — | 1 | — | 1 |
| Optic neuritis | D009902 | EFO_0007405 | H46 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | 3 | — | 2 | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrophy | D001284 | — | — | — | — | — | — | 1 | 1 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 1 | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 1 | 1 |
| Driving under the influence | D000066448 | — | — | — | — | — | — | 1 | 1 |
| Prenatal exposure delayed effects | D011297 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Interferon beta-1a |
| INN | — |
| Description | Interferon beta precursor (IFN-beta) (Fibroblast interferon) |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201562 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00060 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Avonex – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
215,652 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use